Morningstar

Guardant Health Inc GH

Morningstar Rating
Unlock
Stock XNAS Rating as of
$155.87 +0.87 (0.56%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Guardant Health Leads the Way in Blood-Based Single Cancer Screening

Jay Lee

Guardant Health is a leader in liquid biopsy. It has market-leading platforms in tumor genomic profiling, molecular residual disease, or MRD, testing, and colorectal cancer screening. Although these are promising markets with multibillion-dollar revenue potential, it is still the early days with considerable uncertainty surrounding the details of payer coverage and guideline inclusion. We do not expect the company to generate positive cash flows until 2028.

Read Full Report

Price vs Fair Value

View History
GH is trading at a LOCK|L#!?&S premium.
Price
$155.87
Fair Value
ls
Uncertainty
LOCK|GH <n$Gt
1-Star Price
LOCK|N.Kh
5-Star Price
Pk
Economic Moat
LOCK|!Xd
Capital Allocation
LOCK|#$>>?Rg

Bulls Say, Bears Say

Bulls

Guardant is a leader in liquid biopsy, has been a step ahead of the competition, and is making steady progress toward profitability around 2028.

Bears

Guardant’s Shield could face stiff competition if multicancer early-detection tests eventually achieve comparable sensitivity and pricing.

Show More

Trading Information

Previous Close Price
$155.00
Day Range
$149.78–157.33
52-Week Range
$40.36–174.08
Bid/Ask
$150.00 / $156.50
Shares Outstanding
132.60M
Market Cap
$20.67B
Volume/Avg
2M / 3M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
18.36
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
2,506
Website
https://www.guardanthealth.com

Competitors

Valuation

View More
Metric
GH
ILMN
Price/Earnings (Normalized)
 —37.11
Price/Book Value
 —10.60
Price/Sales
 18.366.58
Price/Cash Flow
 —22.60
Price/Earnings
GH
ILMN

Financial Strength

Metric
GH
ILMN
Quick Ratio
 4.251.21
Current Ratio
 4.681.75
Interest Coverage
 −104.6611.20
Quick Ratio
GH
ILMN

Profitability

Metric
GH
ILMN
Return on Assets (Normalized)
 −14.32%13.27%
Return on Equity (Normalized)
 —33.85%
Return on Invested Capital (Normalized)
 −20.78%17.57%
Return on Assets
GH
ILMN

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|w%hP#!xBLOCK|>r$198B
 Danaher Corp
DHR
LOCK|qh!cV!!YLOCK|##^$144B
 IDEXX Laboratories Inc
IDXX
LOCK|>St$dv>LOCK|RGh$45B
 Agilent Technologies Inc
A
LOCK|$>>syJ#HLOCK|g>$37B
 Waters Corp
WAT
LOCK|WV#Gn<LOCK|R^#$36B
 IQVIA Holdings Inc
IQV
LOCK|!xS>dKRLOCK|<$HD$34B
 Illumina Inc
ILMN
LOCK|YsDDj!LOCK|^b$t$28B
 Mettler-Toledo International Inc
MTD
LOCK|&v&!LfJLOCK|@<$%#$26B
 Quest Diagnostics Inc
DGX
LOCK|<dWY$^$LOCK|>p<k!$23B
 Labcorp Holdings Inc
LH
LOCK|$GmR!g&$LOCK|#<?Y&$23B

Sponsor Center